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INTRODUCTION
Most of the studies on primary hyperpatathyroidism (PHPT) 
and parathyroidectomy are generally of West Europe or North 
America origin. Therefore, when the clinical and laboratory 
presentations of the disease are defined, the data are generally 
from North American and Western Europe [1,2]. However, it 
has been demonstrated in comparative studies that PHPT may 
have different clinical presentations in different geographical 
regions [1,3-5]. For example, in a study comparing the female 
cases with PHPT between New York, United States, and Beijing, 
China, clinical findings such as osteoporosis, urolithiasis and 
osteitis cystica fibrosa were found to be more frequent, the 
parathormone (PTH) and Ca+2 levels were found to be higher, 
and 25-hydroxyvitamin D (25(OH)D) level was found to be 
lower in women living in Beijing. However, in the same study, 
asymptomatic PHPT was found to be more common in women 
living in New York [1]. Likewise, in another study comparing 
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patients in San Francisco, United States and Bursa, Türkiye 
matched according to age and gender, osteoporosis was more 
frequent, the PTH level was higher, the phosphorus level was 
lower, and the adenoma sizes were larger in patients living 
in Bursa [3]. However, such studies conducted in a certain 
region of countries may not give enough information for the 
whole country. Of this socio-economic, ethnic or climate-
related differences may be observed in patients of different 
geographical regions of a country with a large surface area. This 
may lead to the presentation diseases with different clinical 
and laboratory findings within the same country. 
Considering this subject, the present information in the 
literature is insufficient with regard to the clinical, laboratory, 
and operational data of the patients operated on due to PHPT 
that reflect the general population of Türkiye. Furthermore, 
no difference was considered for the clinical presentation of 
the disease in different geographical regions of Türkiye, which 
is a quite large country with regard to the surface area and 
population. The aim of this study was to define the clinical 
and laboratory characteristics of patients operated on for 
PHPT at university hospitals in Türkiye, and to investigate the 
differences in the clinical presentations of the disorder between 
different geographical regions. 
METHODS
The study included patients operated on for PHPT at univer-
sity hospitals in Türkiye between January 2004 and December 
2008. The data were obtained from patient files and electronic 
records retrospectively. The number of general surgical 
operations between the dates of the study in participating 
hospitals was also recorded. The participating hospitals had 
recorded the data in a standard electronic form, in the Excel 
program. The demographic, clinical, laboratory and operational 
findings of the whole country and regions of Türkiye were 
investigated. Additionally, comparisons were performed with 
regard to the general country and different regions. The study 
was approved by the Ethical Committee of Scientific Researchs 
of the hospital in charge. 
Determining the centres to provide data to the  
study 
The number of patients operated on due to PHPT in Türkiye 
is limited. The diagnosis and treatment of the disease is 
generally performed by certain reference medical centres. There-
fore, university hospitals in different regions of the country, 
which are believed to be reference centres, were included in 
the study in order to obtain larger patient series. A total of 25 
university hospitals to be included in the study; however, only 
21 universities agreed to participate. One of the 21 hospitals 
had insuffient data and was therefore excluded. The study was 
completed with a total of 20 university hospitals. 
Determining the regions 
The classically predefined 7 regions were considered when 
investigating the distribution of the disease throughout 
Türkiye. However, the East Anatolian region and the Southeast 
Anatolian region were combined, since the data of patients 
with PHPT obtained in each region were considered to be 
insuffiecient, and named East-Southeast Anatolian region. 
Accordingly, the country was then divided into 6 regions. 
Besides this, centres in the Karadeniz region could not provide 
sufficient data, and therefore, this region was not included, and 
Türkiye was investigated as 5 regions (Table 1). 
Presentation of data on tables
Since this study was retrospective, the total number of cases 
investigated for each parameter was different. Therefore, for 
certain parameters investigated, the total number of patients 
who possessed data for those parameters was expressed in the 
tables. 
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Table 1. Distribution of cases according to regions and uni-
versity hospitals in Türkiye
Region/city      No. of  cases (%)
Marmara region 434 (37.3) 
  İstanbul University, Cerrahpasa Medical 
   Faculty/İstanbul
75
  İstanbul University Medical Faculty/İstanbul 157
  Marmara University/Istanbul 27
  Kocaeli University/Kocaeli 75
  Uludag University/Bursa 100
Aegean region 150 (12.9)
  Ege University/Izmir 75
  Adnan Menderes University/Aydin     35
  Pamukkale University/Denizli 40
Mediterranean region 67 (5.8)
  Cukurova University/Adana 44
  Mersin University/Mersin 23
Central anatolia region   396 (34.1)
  Erciyes University/ Kayseri 70
  Hacettepe University/Ankara 112
  Ankara  University/Ankara   95
  Gazi University/Ankara 75
  Osmangazi University/Eskisehir 19
  Cumhuriyet University/Sivas 25
East-Southeast anatolian region        115 (9.9)
  Atatü University/Erzurum 53
  Dicle University/Diyarbakir    8
  Gaziantep University/Gaziantep           16
  Firat University/Elazig            38
Total        1,162
10
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Statistical analysis
The comparisons were performed between the general data 
of Türkiye and the data of the regions. Interregional compari-
sons were performed as well. The continuous variables were 
expressed as mean ± standard error or median (range), while 
the categorical variables were presented as frequency with 
related percentage. The comparisons between the groups were 
performed using the Kruskal-Wallis or the analysis of variance 
(ANOVA) test, to determine whether the variables followed a 
normal distribution or not. The Bonferroni test was performed 
for multiple comparisons after the ANOVA test. Two-group 
comparisons were performed using the Mann-Whitney test. 
The comparisons of the categorical variables between the 
groups were performed using the Fisher-Freeman-Halton test, 
the Pearson chi-square test or the Fisher Exact test. Statistical 
analyses were also performed using IBM SPSS Statistics ver. 21.0 
(IBM Co., Armonk, NY, USA), and the level of siginificance was 
set at α=0.05.
RESULTS
The general surgery clinics of 20 university hospitals from 
5 different regions were included in the study. The total num-
ber of cases investigated was 1,228. However, 66 cases were 
excluded due to various reasons such as high creatinine levels 
or the operation date being out of the interval accepted in the 
study. Therefore, the total number of cases included was 1,162. 
When the distribution of the cases according to the regions 
was investigated, regions with the highest number were the 
Marmara (n=434, 37.3%) and the Central Anatolian regions 
(n=396, 34%). The region with the lowest number was the 
Mediterranean (n=67, 5.8%) (Table 1). However, it should be 
considered that the cases of East and Southeast Anatolia were 
combined and the data were included as the East-Southeast 
Anatolian Region. 
Thirteen out of 20 centres participating in the study had 
sent the data of general surgical operations performed within 
the dates of the study. According to these data, 169,527 
general surgical operations and 732 parathyroidectomies 
were performed. These data indicate that the rate of para-
thyroidectomies performed due to PHPT in the university 
hospitals of Türkiye among all general surgical operations was 
0.4%. The distribution in years indicated that the number of 
cases operated due to PHPT in Türkiye increased (Fig. 1). 
Demographic and clinical findings
Nine hundred fifty-seven of the cases (82.4%) operated on due 
to PHPT in the university hospitals of Türkiye were women and 
205 (17.6%) were men. No difference was determined between 
the regions with regard to gender (P > 0.05).
The mean age was 52.4 ± 0.38 years. The mean ages of the 
women and men were 52.07 ± 0.42 and 54.03 ± 0.38 years, 
respectively, which indicated no statistical significance (P = 
0.542). Cases in the East-Southeast Anatolian Region were 
observed to be younger than the cases in both Türkiye’s general 
area and Marmara, Aegean and Central Anatolian Regions (P 
< 0.001). The Mediterranean Region included the youngest 
patients following East-Southeast Anatolian Region, and had 
similar age with the remaining regions (Table 2). 
The rate of cases operated on due to recurrence or persistent 
PHPT in the university hospitals of Türkiye was 3.9%. No 
difference was detected between the regions (P = 0.377) or 
Table 2. Demographic and clinical data of patients undergoing surgery for PHPT at university hospitals in Türkiye
Variable Türkiye 1 2 3 4 5 P-valuea) P-valueb)
Female/male 957/205 369/65 117/33 51/16 322/74 98/17 0.146 0.054
Age (yr) 52.4 ± 0.38 52.4 ± 0.63 53.9 ± 1.01 50.1 ± 1.50 53.7 ± 0.64 46.8 ± 1.34 <0.001 <0.001
Previous PTx 43/1,116 (3.9) 21/428 (4.9) 4/110 (3.6) 2/67 (3) 15/396 (3.8) 1/115 (0.9) 0.377 0.522
Hypertension 388/1,100 (35.3) 138/399 (34.6) 52/147 (35.4) 26/57 (45.6) 139/391 (35.5) 33/106 (31.1) 0.469 0.614
Urolithiasis 206/1,109 (18.6) 84/420 (20) 29/146 (19.9) 21/47 (44.7) 54/385 (14) 18/111 (16.2) <0.001 <0.001
Values are presented as mean±standard error or number/N (%).
PHPT, primary hyperparathyroidism; PTx, parathyroidectomy; N, total cases who have data related that parameter. 
Regions: 1, Marmara; 2, Aegean; 3, Mediterranean; 4, Central Anatolia; 5, East-Southeast.
a)Comparison among regions. b)Comparison between Türkiye and regions. 
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Fig. 1. Distribution of patients with primary hyper pata thy-
roidism according to years and regions in Türkiye.
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between Türkiye in general and its regions (P = 0.522) (Table 2).
In 35% of the cases with PHPT, hypertension was present 
in the general area. This rate varied between 31% and 45% in 
different regions. However, no difference was observed between 
the regions or between the general country and regions with 
regard to hypertension (P > 0.05).
Of the cases operated due to PHPT in the university hospitals 
of Türkiye, 18.6% had a history of urolithiasis. The incidence of 
urolithiasis was significantly different between the regions (P 
< 0.001). The highest incidence belonged to the Mediterranean 
Region (44.7%), and the lowest incidence belonged to the 
Central Anatolian Region (14%). The incidence of urolithiasis 
was higher in the Mediterranean Region compared to Marmara, 
Aegean, Central Anatolia and East-Southeast Anatolia Regions 
(P < 0.001, P = 0.001, P < 0.001, and P < 0.001, respectively). 
The incidence in the Central Anatolian region was lower than 
that of the Marmara Region (P = 0.025). No other difference 
was observed between the regions. Compared to the general 
country, the incidence of urolithiasis was lower in the Central 
Anatolian region and higher in the Mediterranean Region (P = 
0.043, P < 0.001, respectively) (Table 2). 
Bone findings 
The bone density findings of 688 out of 1,162 patients were 
present. In patients operated on due to PHPT in Türkiye, 
the rates of detection of abnormal findings (osteopenia or 
osteoporosis) in femur, vertebrae or radius with dual-energy 
X-ray absorbtiometry (DXA) were 67.6%, and 54% had osteo-
porosis (Table 3). The incidence of osteopororis in the regions 
except the Marmara Region was higher than the incidence of 
osteopenia. When the abnormal DXA findings of these cases 
were investigated, differences were observed between both 
the regions and the general country. The rates of patients with 
reduced bone mineralization in the Marmara and Mediter-
ranean Regions were higher than that of Türkiye’s gene ral (P < 
0.001 and P = 0.037, respectively). This rate was lower in the 
Central Anatolian Region than that of Türkiye’s general region (P 
< 0.001). No significant difference was observed in the Aegean 
and East-Southeast Anatolian Regions compared to Türkiye’
s general region (P = 0.884 and P = 0.862, respectively). 
Differences were observed in the interregional comparisons 
with regard to the reduced bone mineralization rates. The 
Mediterranean and Marmara Regions had the highest rate of 
abnormal DXA findings. This rate was higher in the Marmara 
Region than Aegean, Central Anatolian and East-Southeast 
Regions (P = 0.003, P < 0.001, and P = 0.010, respectively). 
The lowest rate of abnormal bone density was observed in 
the Central Anatolian Region (39.5%). The differences were 
observed between the Central Anatolian Region and the 
Marmara, Mediterranean and East-Southeast Anatolian Regions 
(P < 0.001, P < 0.001, and P = 0.002, respectively). The highest 
rates of osteoporosis were observed in the Aegean (76.8%) and 
the Central Anatolian (68.5%) Regions. 
The rate of patients with a history of bone fracture among 
those operated on due to PHPT in Türkiye was found to be 6%. 
When Türkiye’s general region and the regions were compared, 
only the Central Anatolian Region had a higher bone fracture 
rate (11.6%) (P = 0.036). The interregional comparisons revealed 
significant differences in the frequency of patients with a 
history of bone fracture (P = 0.004). The rate of patients with 
a history of bone fracture was higher in the Central Anatolian 
Region than the Marmara (P = 0.019), Aegean (P = 0.039) and 
the East-Southeast Anatolian (P = 0.019) Regions, higher in the 
Mediterranean Region than the Aegean Region (P = 0.050), and 
higher in the Mediterranean Region than the East-Southeast 
Anatolian Region (P = 0.021) (Table 3).
The rate of bone cyst among patients operated on due to 
PHPT in Türkiye was found to be 1.5%. The interregional 
comparisons revealed a higher rate of bone cyst in the Central 
Anatolian Region than the Marmara Region (P < 0.001). No 
difference was observed between the remaining regions (Table 3). 
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Table 3. Bone findings in patients undergoing surgery for PHPT at university hospitals in Türkiye 
 Variable Türkiye
Region 
P-valuea) P-valueb)
1 2 3 4 5
DXA
  Abnormal 465/688 (67.6) 269/328 (82) 69/101 (68.3) 20/22 (90.9) 73/185 (39.5) 34/52 (65.4) <0.001 <0.001
  Osteopenia 214 (46.0) 144 (53.5) 16 (23.2) 8 (40.0) 23 (31.5) 23 (67.6) <0.001 <0.001
  Osteoporosis 251 (54.0) 125 (46.5) 53 (76.8) 12 (60.0) 50 (68.5) 11 (32.4)
Fracture 62/971 (6.0) 19/386 (4.7) 5/141 (3.4) 5/38 (11.6) 31/301 (9.3) 2/105 (6.0) 0.004 0.010
Bone cyst 14/943 (1.5) 1/422 (0.2) 1/132 (0.8) 0/41 (0) 10/243 (4.0) 2/105 (1.9) 0.003 0.009
Values are presented as number/N (%).
PHPT, primary hyperparathyroidism; DXA, dual-energy X-ray absorptiometry; N, total cases who have data related that parameter. 
Regions: 1, Marmara; 2, Aegean; 3, Mediterranean; 4, Central Anatolia; 5, East-Southeast.
a)Comparison among regions. b)Comparison between Türkiye and regions. 
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Parathormone 
The median PTH value in patients operated on in the univer-
sity hospitals of Türkiye was found to be 220 pg/mL (range, 70–
2,500 pg/mL). The regions with the highest and lowest median 
PTH values were the East-Southeast Anatolian Region (375 pg/
mL) and the Mediterranean Region (180 pg/mL), respectively 
(Table 4). Differences were observed in the median PTH values 
between both Türkiye’s general area and the regions, and 
between the regions (<0.001) (Tables 4, 5). The normal labo-
ratory value of PTH was accepted as 35–68 pg/mL. 
Calcium
The median serum total Ca+2 levels of the patients operated 
in the university hospitals of Türkiye was 11.2 mg/dL (range, 
9.5–15.1 mg/mL). The Ca+2 value observed in all of the regions 
was 11 mg/dL or more. The region with the highest median Ca+2 
value was the Mediterranean region (12.1 mg/dL). Differences 
were observed between both the Mediterranean Region and 
the other regions, and the Mediterranean Region and Türkiye’
s general region (P < 0.05) (Tables 4, 5). The median values of 
the remaining regions were closer to Türkiye’s general region. 
The median values of Ca+2 in the 24-hour urine of the patients 
ope rated on due to PHPT in the university hospitals of Türkiye 
was 345 mg/24 hr (range, 40–1,385 mg/24 hr). No difference was 
observed between the regions (P > 0.05). The normal laboratory 
values for the total serum Ca+2 and urinary Ca+2 were accepted 
as 8.4–10.2 mg/dL and 100–300 mg/24 hr, respectively. 
Phosphorus
The median serum phosphorus value in patients operated on 
due to PHPT in Türkiye was 2.4 mg/dL (range, 1–4.7 mg/dL). The 
regions with the lowest and highest median phosphorus values 
were the East-Southeast Anatolian and the Aegean Regions, 
respectively. Inter-regional differences were observed in the 
median phosphorus values (P < 0.05). The normal laboratory 
values of phosphorus was accepted as 2.3–4.7 mg/dL. 
 
25-hydroxyvitamin D 
The median value of 25(OH)D among patients operated on 
due to PHPT in Türkiye was 15 ng/mL (range, 3–98 ng/mL). The 
regions with the lowest median 25(OH)D level were the Mar-
mara with 11 ng/mL (range, 4–98 ng/mL) and the East-Southeast 
Anatolian with 11 ng/mL (range, 3–24 ng/mL), whereas the 
region with the highest median 25(OH)D level was the Aegean 
Region with 31 ng/mL (range, 8–59 ng/mL) (Table 4). 25(OH)D 
deficiency was observed in 63% of the patients operated on due 
to PHPT in Türkiye’s general region. The incidence of 25(OH)D 
deficiency was higher in the Marmara and the East-Southeast 
Anatolian Regions compared to Türkiye’s general region (P = 
0.023 and P = 0.043, respectively). The inci dence of 25(OH)D 
deficiency was significantly lower in the Aegean, Mediterranean 
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and Central Anatolian Regions compared to Türkiye’s general 
region (P = 0.026, P = 0.002, and P = 0.006, respectively). A 
blood level of 25(OH)D ≤ 20 ng/mL was accepted as 25(OH)D 
deficiency in this study. 
The number of patients with 25(OH)D deficiency was 
significantly different between the regions (P < 0.001). 25(OH)
D deficieny was observed in the Aegean and the Mediterranean 
Regions with the lowest rate (Table 4). The East-Southeast 
Anatolian (86%) and the Marmara (72%) Regions were the 
regions with highest rates of 25(OH)D deficiency. 25(OH)D 
deficiency was higher in the Marmara Region compared to the 
Aegean, Mediterranean and Central Anatolian Regions (P = 
0.004, P < 0.001, and P < 0.001, respectively). No difference 
was observed between the Marmara and the East-Southeast 
Anatolian Regions (P = 0.237). The incidence of 25(OH)D 
deficiency was higher in the East-Southeast Anatolian Regions 
compared to the Aegean, Mediterranean and the Central 
Anatolian Regions (P = 0.001, P < 0.001, and P = 0.002, 
respectively). No difference was observed between the Aegean 
Region and the Mediterranean and Central Anatolian Regions 
(P = 0.338 and P = 1.000, respectively). No difference was 
observed between the Central Anatolian and the Mediterranean 
Regions (P = 0.205) (Table 4).
Alkaline phosphatase 
The median level of ALP among patients operated due to 
PHPT in the university hospitals of Türkiye was determined 
to be 116 U/L (range, 10–299 U/L). Regions with the highest 
median ALP levels were the Mediterranean (229 U/L; range, 
48–1,567 U/L) and the East-Southeast Anatolian (201 U/L; range, 
10–2,990 U/L) Regions. The ALP levels observed in these 2 
regions were significantly higher compared to the remaining 
regions (P < 0.05). The ALP levels were found to be higher than 
the normal level in 37% of the patients operated in Türkiye’s 
general region. The number of cases with an ALP level higher 
than normal was highest in the East-Southeast Anatolian (68%) 
and the Mediterranean (71%) Regions (Tables 4, 5). The normal 
laboratory values of ALP was accepted as 25–100 U/L. 
Operative findings 
The rates of single adenoma, multiple adenoma and hyper-
plasia in patients operated on due to PHPT in the university 
Table 5. P-values of comparisons for laboratory data among regions in Türkiye 
Regions Vit D Urine Ca+2 PTH Ca+2 P ALP
1–2 0.001 0.431 0.705 0.434 0.001 0.927
1–3 <0.001 0.487 0.008 <0.001 0.243 <0.001
1–4 <0.001 0.556 0.002 0.861 0.008 0.172
1–5 0.278 0.298 <0.001 0.196 0.002 <0.001
2–3 0.749 0.903 0.054 <0.001 0.162 <0.001 
2–4 0.032 0.721 0.103 0.401 0.228 0.276
2–5 <0.001 0.831 <0.001 0.610 <0.001 <0.001
3–4 0.011 0.689 0.376 <0.001 0.604 <0.001 
3–5 <0.001 0.979 <0.001 <0.001 0.002 0.490
4–5 <0.001 0.624 <0.001 0.171 <0.001 <0.001 
PTH, parathormone; Ca+2, calcium; Vit, vitamin; P, phosphorus.
Regions: 1, Marmara; 2, Aegean; 3, Mediterranean; 4, Central Anatolia; 5, East-Southeast.
Table 6. Operative findings in patients undergoing parathyroidectomy for PHPT at university hospitals  in Türkiye  
 Variable Türkiye
 Region 
P-valuea) P-valueb) 
1 2 3 4 5
Adenom 
  Single 1,028/1,146 (90) 377/431 (87) 136/146 (93) 59/66 (89) 353/388 (91) 103/115 (90) >0.05 >0.05 
  Multiple 103/1,146 (9) 51/431 (12) 10/146 (7) 7/66 (11) 23/388 (6)  12/115 (10) >0.05 >0.05 
  Hyperplasia 15/1,146 (1) 3/431 (1) 0/146 (0) 0/66 (0) 12/388 (3) 0/115 (0) >0.05 >0.05 
Dimention (mm) 16 (4–70)/928 16.5 (4–70)/394 20 (6–60)/118 15 (7–65)/61 15 (5–65)/249 20 (7–40)/106 <0.001 <0.001 
Thyroidectomyc) 342/958 (36) 88/277 (32 ) 49/108 (45) 22/67 (33) 134/391 (34) 49/115 (43) >0.05 >0.05 
Values are presented as number/N (%) or median (range)/N.
PHPT, primary hyperparathyroidism; N, total cases who have data on that parameter.
Regions: 1, Marmara; 2, Aegean; 3, Mediterranean; 4, Central Anatolia; 5, East-Southeast.
a)Comparison among regions. b)Comparison between Türkiye and regions. c)Thyroidectomy means concurrent thyroidectomy.
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hospitals of Türkiye were 90%, 9%, and 1%, respectively. No 
difference was observed between the regions (P > 0.05) 
(Table 6). The median adenoma size in the longest axis was 
16 mm (range, 4–70 mm). Regions with the largest adenoma 
size were the Aegean (20 mm; range, 6–60 mm) and the East-
Southeast Anatolian (20 mm; range, 7–40 mm) Regions. The 
median adenoma sizes observed in these 2 regions were 
higher than those of the Mediterranean and Central Anatolian 
Regions (P < 0.001). No statistical difference was observed 
between Türkiye’s general area and the regions (P > 0.05). 
Concomitamt thyroidectomy was performed for 36% of the 
patients undergoing the PHPT operation for different reasons. 
No difference was observed between the regions with regard to 
concomitant thyroidectomy (P > 0.05). 
DISCUSSION
The age of patients with PHPT is greater in Western Coun-
tries (USA, 60–62; Germany, 59; Italy, 59; Denmark, 65) than 
Eastern countries (China, 37; India, 38) [1,6-11]. In this study, 
the median age of patients with PHPT was 52. This indicates 
that the age of the patients with PHPT in Türkiye is somewhere 
between Eastern and Western countries. When the regions 
were investigated, the median age of the patients in the East-
Southeast Anatolian Region was significantly younger than 
those of the remaining regions, except for the Mediterranean 
Region. Griebeler et al. [6] reported that the median age of the 
cases in Rochester, America with PHPT was 55 between 1985 
and 1997, which significantly increased by time reaching 60 
between 1998 and 2010. Similarly, in studies conducted in 
China and Hong Kong, the mean age of the patients with PHPT 
had increased in time compared to the previous times [12,13]. 
Another characteristic concerning age was that the patients 
living in regions with a severe form of the disease were younger 
[1,11]. However, it was reported in age and sex matched studies 
that the clinical and laboratory findings of the disease may be 
different [3,4]. There are not many studies investigating the 
factors affecting the difference in age of patients in different 
countries or regions of a country. 
With the use of autoanalysers in the 1970s, a significant 
increase was reported in both the incidence of the cases with 
PHPT and the rate of the asymptomatic cases related to the 
frequent measurement of routine Ca++ [14,15]. This change is 
specifically significant in Western countries including North 
America and North Europe. In the remaining regions of the 
world, the number of classic symptomatic PHPT cases is still 
high despite a partial change [12,16]. For example, the rates of 
kidney stone among patients with PHPT are 3%–20% in USA, 
11% in Germany, 42% in China, and 50% in India [1,8,17,18]. 
In this study, the kidney stone rate in Türkiye was found to 
be 18%. Interregional comparisons have shown that this rate 
differed between 14% and 44%. The region with the highest 
incidence of kidney stone was the Mediterranean Region. 
Mollerup et al. [19] have reported that kidney stone was more 
common among young patients. The Mediterranean Region 
included the second youngest patient group after the East-
Southeast Anatolian Region, although not significantly different 
from the other regions. However, although the ages of patients 
in Türkiye were younger compared to the Western countries, 
and those in the East-Southeast Anatolian Region were younger 
than the other regions, no significant difference was observed 
with regard to the rates of urolithiasis. The differences observed 
in the urolithiasis rates between the regions/countries may 
be related to the different etiological factors in kidney stone 
formation or ineffective radiological evaluation of the kidneys 
in asymptomatic patients [20-22]. 
The bony findings in patients with PHPT may differ between 
countries/regions. For example, the bone mineral density in 
caucasian women with PHPT living in the USA were found to 
be higher than those living in Italy [4]. Bone diseases among 
patients with PHPT have been reported to vary between 5% 
and 8% in the USA [17]. The rate of osteoporosis was 100% in 
China and 50% in Taiwan [1,23]. Bone cyst has been reported in 
each case in India [11]. In this study, bone diseases (osteopenia 
or osteoporosis) were detected in 67% of the cases with PHPT. 
However, when the regions of Türkiye were investigated sepa-
rately, it was observed that the rates of bone disease were 
homogeneous. Furthermore, the rates of bone diseases in the 
Mediterranean (90%) and the Marmara (82%) Regions were 
much higher than the mean of Türkiye. According to these data, 
it may be concluded that the rate of bone diseases in Türkiye 
is somewhere between the eastern and western countries, but 
rather similar to the eastern countries in some regions. 
It has been believed that 25(OH)D deficiency has an impor-
tant role in different severities of PHPT observed among the 
world. In regions where 25(OH)D deficiency is endemic, a 
severe form of the disease is observed, whereas mostly the 
asymptomatic form is observed in western counties [24]. It 
has been reported that 25(OH)D deficiency is an important 
factor defining in particular the bone disease in patients with 
PHPT [9,10,24,25]. Furthermore, a negative correlation is pre-
sent between 25(OH)D levels and the adenoma weight, and 
a positive correlation with PTH, Ca++ and ALP levels [7,19,24-
26]. In this study, the East-Southeast Anatolian Region and the 
Marmara Region were the regions with more frequent patients 
with 25(OH)D deficiency and with more severe PHPT. However, 
the rate of patients with subnormal 25(OH)D levels has been 
reported as 63% in Türkiye, 93% in France, 81% in Denmark, 
33% in Italy, and 86% in China [10,12,26]. When these rates are 
investigated, it is obvious that it is not possible to explain the 
more severe form of the disease observed in eastern countries, 
and the asymptomatic form observed in western countries with 
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25(OH)D deficiency only. Additionally, Mishra et al. [11] claimed 
that 25(OH)D levels were normal despite the severe form of the 
disease in patients with PHPT in India, and thus, additional 
pathogenetic factors may be present in the formation of the 
severe disease. Likewise, although the number of patients with 
25(OH)D deficiency in the Mediterranean Region of Türkiye 
was quite low, this region had the highest rates of urolithiasis, 
bone diseases, blood Ca+2 and ALP levels. Therefore, it should be 
considered that Vitamin D is not the only factor indicating the 
severity of PHPT, delays in access to detection and treatment 
of the disease, and factors such as ethnicity, genetics, and race 
may play a defining role in the severity of the disease as well 
[2,6,27-29]. 
The median PTH and Ca+2 levels in patients with PHPT 
in Türkiye were found to be 220 pg/mL and 11.2 mg/dL, 
respectively. The median Ca+2 in USA was reported to be 
10.8 mg/dL [6]. The median PTH and Ca+2 levels were 134 pg/
mL and 11.4 mg/dL in France, 102 pg/mL and 11 mg/dL in 
Denmark, and 141 pg/mL and 11.1 mg/dL in Italy, respectively 
[9,10,26]. The PTH levels were 20 and 17 fold the normal value 
in China and India, respectively [1,11]. In another study from 
Korea, mean PTH and Ca+2 levels were reported as 263 pg/mL 
and 11.6 mg/dL, respectively [30]. According to these data, no 
significant difference is observed between the blood Ca+2 levels 
of the patients with PHPT in Türkiye and Europe and America; 
however, the PTH levels were higher than those in western 
countries. 
The limitations of this study were: it was retrospective, there 
was a lot of data loss, lower possibilities of interlaboratory 
differences, and the data of the study were old. Due to the 
difficulty of data collection, recent data could not be added. 
However, the data of patients operated on due to PHPT in 
Türkiye’s general and separate regions is not available in the 
literature. We believe that we have contributed to literature in 
this regard. 
In this study, the general characteristics of patients with 
PHPT have been determined, and it has been demonstrated that 
the demographic, clinical and laboratory data of cases living in 
different regions of the same country may not be homogenous. 
As it is known, the patients’ clinical characteristics are under 
the influence of multiple factors such as ethnic, genetic and 
socio-economic statuses, nutritional habits (for example, milk 
consumption), climatic conditions, and the duration of living 
in the region in question. Furthermore, due to the fact that this 
study was retrospective, it has not been possible to evaluate the 
regional differences due to insufficiency of data. In order not to 
be speculative, no comment has been made regarding regional 
differences.. 
In conclusion, the clinical and laboratory characteristics of the 
patients operated due to PHPT in different classically defined 
geographical regions of Türkiye differ. Furthermore, the general 
findings of the cases in Türkiye give us a hint that the severity 
of the disease here is somehwere between Eastern and Western 
countries. This study indicates that the clinical presentation of 
PHPT may vary even in different regions of the same country. 
Therefore, it should be considered when planning such studies 
comparing the differences between regions/countries. 
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